Ywam Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.45 M
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 48.88%
- Profit Growth 11.26%
- Ebitda 13.63%
- Net Worth 1.14%
- Total Assets 9.21%
About Ywam Pharma
Ywam Pharma Private Limited (YPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 March 2012 and has a history of 12 years and ten months. Its registered office is in Akola, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.45 M, as per Ministry of Corporate Affairs (MCA) records.
Girish Gokhale and Bhalchandra Bhave serve as directors at the Company.
Company Details
-
Location
Akola, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85191MH2012PTC228544
-
Company No.
228544
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Mar 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ywam Pharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Girish Gokhale
|
Managing Director | 21-Mar-2012 | Current |
|
Bhalchandra Bhave
|
Managing Director | 21-Mar-2012 | Current |
Board Members
No Directors or KMP associated with company. Upon reviewing the records, we can confirm that there are no Directors or Key Management Personnel (KMP) associated with this company at present.
Financial Performance of Ywam Pharma.
Ywam Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 48.88% increase. The company also saw a substantial improvement in profitability, with a 11.26% increase in profit. The company's net worth moved up by a moderate rise of 1.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ywam Pharma?
In 2023, Ywam Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹0
Charges Breakdown by Lending Institutions
- Bank Of Maharashtra : 0.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Dec 2012 | Bank Of Maharashtra | ₹0.00 | Open |
How Many Employees Work at Ywam Pharma?
Unlock and access historical data on people associated with Ywam Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ywam Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ywam Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.